One patient’s access to Eli Lilly’s experimental obesity drug has sparked a much larger debate
Industry Buzz
[Compassionate use is] usually reserved for terminal illness. ... Often it’s something that may have a marginal pathway towards approval, or a really long time toward approval.
—Jamy Ard, MD, via STAT
It’s rare for a single expanded access decision to spark national headlines. But after Eli Lilly granted an anonymous patient access to its experimental obesity drug retatrutide, questions about who received the therapy quickly evolved into a broader debate over fairness, transparency, and the purpose of compassionate use programs.[]
The debate began after STAT reported that Eli Lilly had granted compassionate use access to retatrutide for an unnamed 79-year-old man outside of a clinical trial.[]
The report prompted widespread speculation that the recipient was President Donald Trump. However, White House spokesperson Kush Desai denied the allegation, stating that the compassionate use application was “not for the President.”[][][]
Administration officials have since reiterated that Trump did not receive the drug through Eli Lilly’s expanded access program, and no public evidence has identified the anonymous patient as the president.[][][]
Related: How to prepare your practice for growing demand of GLP-1 medicationsAn anonymous patient sparked a political firestorm
Retatrutide is Eli Lilly’s investigational triple hormone receptor agonist. Still in phase 3 development, the once-weekly injectable has generated considerable interest after phase 2 data demonstrated mean weight loss approaching 24% at 48 weeks, along with improvements in several cardiometabolic risk factors.[]
According to STAT, a senior clinician at the NIH requested expanded access to treat a patient for refractory obesity with obstructive sleep apnea and pulmonary hypertension.[] The application reportedly stated that the patient had previously been treated with tirzepatide and was not considered an appropriate candidate for bariatric surgery.
Eli Lilly’s decision to approve the request was unusual enough to prompt questions from bioethicists and regulatory experts about how the case met the company’s compassionate use criteria.
“[Compassionate use is] usually reserved for terminal illness. … Often it’s something that may have a marginal pathway towards approval, or a really long time toward approval,” Jamy Ard, MD, chief science officer at Advocate Health, told STAT.[]
After the report was published, online speculation centered on President Trump, fueled by the patient’s age and public observations about the president’s recent weight loss.[][][]
Eli Lilly has not identified the recipient, citing privacy obligations.[]
Related: The GLP-1 side effect patients will ask about next: Coincidence or clinical signal?Why the case has drawn attention to expanded access
Although the White House has denied the allegations, the reports also prompted congressional scrutiny.
Sen. Maggie Hassan sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. requesting information about how the expanded access authorization was granted and whether any individual received preferential treatment.[][]
The controversy highlights renewed attention on the FDA’s expanded access pathway. Expanded access—sometimes called compassionate use—allows patients with serious or immediately life-threatening diseases or conditions to receive investigational therapies outside of clinical trials when no satisfactory alternatives exist and when the potential benefits are judged to outweigh the risks.[]
Requests typically require support from the treating physician, agreement from the drug manufacturer, institutional review board oversight, and FDA authorization.[]
Eli Lilly’s compassionate use program evaluates requests individually rather than guaranteeing access to investigational products.[]
Although the identity of the expanded-access recipient remains unknown, the controversy underscores how quickly high-profile cases can shift public attention toward the ethics, transparency, and oversight of compassionate use programs.
For physicians who counsel patients about investigational therapies or submit expanded access requests, the debate serves as a reminder that these pathways can attract scrutiny well beyond the clinic.
Related: Play Now: GLP-1 Hype vs Hard Evidence